Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein
- PMID: 11735247
- DOI: 10.1054/ghir.2001.0244
Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein
Abstract
Chromosomal translocations that disrupt the molecular organization of transcription factors are typical of a variety of solid and hematopoietic cancers. Alveolar rhabdomyosarcoma (ARMS), a paediatric soft tissue malignant tumour, is characterized by the recurrent translocation t(2;13)(q35;q14) that fuses the 5' DNA binding domain-encoding sequences of the Pax3 gene with the 3' sequences of the FKHR gene. The insulin-like growth factor (IGF) system has an important role in muscle development as well as in the aetiology of paediatric sarcomas, including ARMS. In the present study the potential regulation of the IGF-I receptor (IGF-I-R) gene by PAX3-FKHR at the transcriptional level was investigated. PAX3-FKHR was able to transactivate the IGF-I-R promoter in sarcoma-derived cell lines, whereas PAX3 exhibited a reduced potency in comparison to the fusion protein. Furthermore, transfection of the chimera induced a significant increase in the endogenous levels of IGF-I-R protein, suggesting that the IGF-I-R gene is a physiologically-relevant molecular target for the PAX3-FKHR oncogene.
Copyright 2001 Harcourt Publishers Ltd.
Similar articles
-
The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.Oncogene. 1995 Aug 3;11(3):545-52. Oncogene. 1995. PMID: 7630639
-
Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.Oncogene. 1995 Jul 6;11(1):119-30. Oncogene. 1995. PMID: 7624119
-
The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.Mol Cell Biol. 1995 Mar;15(3):1522-35. doi: 10.1128/MCB.15.3.1522. Mol Cell Biol. 1995. PMID: 7862145 Free PMC article.
-
Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.Oncogene. 2001 Sep 10;20(40):5736-46. doi: 10.1038/sj.onc.1204599. Oncogene. 2001. PMID: 11607823 Review.
-
New genetic tactics to model alveolar rhabdomyosarcoma in the mouse.Cancer Res. 2005 Sep 1;65(17):7530-2. doi: 10.1158/0008-5472.CAN-05-0477. Cancer Res. 2005. PMID: 16140913 Review.
Cited by
-
Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options.Oncotarget. 2016 Jul 19;7(29):46263-46272. doi: 10.18632/oncotarget.10089. Oncotarget. 2016. PMID: 27323832 Free PMC article.
-
The role of IGF-1R in pediatric malignancies.Oncologist. 2009 Jan;14(1):83-91. doi: 10.1634/theoncologist.2008-0189. Epub 2009 Jan 6. Oncologist. 2009. PMID: 19126579 Free PMC article. Review.
-
Childhood rhabdomyosarcoma: recent advances and prospective views.J Dent Res. 2012 Apr;91(4):341-50. doi: 10.1177/0022034511421490. Epub 2011 Sep 13. J Dent Res. 2012. PMID: 21917598 Free PMC article. Review.
-
Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.Int J Mol Sci. 2025 May 28;26(11):5204. doi: 10.3390/ijms26115204. Int J Mol Sci. 2025. PMID: 40508013 Free PMC article. Review.
-
Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options.Oncogenesis. 2015 Mar 30;4(3):e145. doi: 10.1038/oncsis.2015.2. Oncogenesis. 2015. PMID: 25821947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous